Skip to main content

Written question asked by Iris Robinson (Democratic Unionist Party) on Friday, 12 September 2003, in the House of Commons. It was due for an answer on Monday, 6 October 2003. It was answered by Stephen Ladyman (Labour) on Monday, 6 October 2003 on behalf of the Department of Health.


Dept of Health

Question
To ask the Secretary of State for Health, what the (a) short and (b) long-term adverse effects are described with methylphenidate.
Answer

Mrs. Iris Robinson: To ask the Secretary of State for Health what the (a) short and (b) long-term adverse effects are described with Methylphenidate. [130260] Dr. Ladyman: Methylphenidate (sold in the UK as Ritalin, Equasym and Concerta XL) is licensed for use in children over six years of age as part of a comprehensive treatment programme for attention deficit hyperactivity disorder, where remedial measures alone prove insufficient. The most common short-term adverse effects generally occur at the beginning of treatment, and include central nervous system effects, such as nervousness and insomnia, and gastro-intestinal effects, such as abdominal pain, nausea and vomiting. The long-term safety and efficacy profiles of methylphenidate are not fully known. This is reflected in the product information of Ritalin provided to prescribers which advises that patients requiring long- term therapy should be carefully monitored. It warns of the risk of moderately reduced weight gain and slight growth retardation with the long-term use of stimulants in children and that careful monitoring of growth is recommended. It also recommends that blood tests should be performed periodically during long-term use.


Secondary information

Type
Written question
Reference
130260; 410 c1320-1W
Session
2002-03
Subjects
Drugs Side effects Methylphenidate
Link
View this Written question on www.publications.parliament.uk